# Does Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year?

> **NCT05174195** · NA · TERMINATED · sponsor: **University Hospital, Geneva** · enrollment: 67 (actual)

## Conditions studied

- Contraception
- Progestogen Adverse Reaction

## Interventions

- **DRUG:** Desogestrel 0.075 milligram
- **DRUG:** Implanon NXT® subdermal implant

## Key facts

- **NCT ID:** NCT05174195
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-15
- **Primary completion:** 2018-03-01
- **Final completion:** 2019-09-30
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** difficult recruitment
- **Last updated:** 2021-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05174195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05174195, "Does Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year?". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05174195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*